米非司酮治疗子宫肌瘤的临床效果分析

Clinical effect of mifepristone in treatment of uterine leiomyoma

目的探讨米非司酮治疗子宫肌瘤的临床效果。方法选取2014年1月至2015年1月于本院就诊的52例子宫肌瘤患者,所有患者在月经第1~3天,每晚睡前口服米非司酮10 mg,连续治疗3个月,对比分析治疗前、后子宫及肌瘤的体积,测定治疗前、后的雌激素(E_2)、雄激素(T)、泌乳素(PRL)、卵泡刺激素(FSH)、孕酮(P)及黄体生成素(LH)的水平,监测治疗后的血、尿常规及肝肾功能指标。结果治疗后患者子宫及肌瘤的体积均较治疗前显著缩小(分别缩小26.84%和45.85%)(P<0.05);血清FSH、LH、P、E_2水平较治疗前显著下降(P<0.05),T和PRL水平变化不明显(P>0.05);治疗后,血、尿常规及肝功能检查均正常。结论米非司酮治疗子宫肌瘤疗效确切,副反应小,值得临床推广应用。

Objective To study the clinical effect of mifepristone in the treatment of uterine leiomyoma. Methods Fiftytwo cases of patients with uterine leiomyoma in our hospital from January 2014 to January 2015 were selected. All the patients received 10 mg mifepristone daily for 90 days beginning on the first 3 days of menstrual cycle. The uterine volume and leiomyoma volume, the serum estrogen （E2）, Testosterone （T）, prolaction （PRL）, follicle-stimulating hormone（FSH）, progesterone （P）, luteinizing hormone （LH） were detected after the treatment; the blood, urine routine test and liver, renal function were monitored after the treatment. Results After treatment, the uterine volume and leiomyoma volume were significantly decreased （26.84% and 45.85% respectively） （P〈0.05）; serum FSH, LH, P, E2 at the end of treatment were significantly less than those before the treatment （P〈0.05）, whereas T and PRL has no significant difference （P〉0.05）. There was no abnormity in blood and urine routine test and liver and renal function. Conclusion Mifepristone is a safe and effective drug on uterine leiomyoma, with low adverse reaction, and it can be used widely in clinic.